Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.

1. Uffmann M, Rasche M, Zimmermann M, von Neuhoff C,

Creutzig U, Dworzak M, et al. Therapy reduction in patients with

Down syndrome and myeloid leukemia: the international ML-DS

2006 trial. Blood .2017;129:3314–21.

2. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K,

et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431

trial. Blood .2017;129:3304–13.

3. Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H,

et al. Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down

Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of. . .

4.

5.

6.

7.

8.

9.

syndrome: a nationwide prospective study in Japan. Pediatr Blood

Cancer. 2016;63:248–54.

Taga T, Saito AM, Kudo K, Tomizawa D, Terui K, Moritake H,

et al. Clinic al characteristics and outcome of refractory/relapsed

myeloid leukemia in children with Down syndrome. Blood.

2012;120:1810–5.

Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard

DR, et al. Increased age at diagnosis has a significantly negative

effect on outcome in children with Down syndrome and acute

myeloid leukemia: a report from the Children’s Cancer Group

Study 2891. J Clin Oncol. 2003;21:3415–22.

Blink M, Zimmermann M, von Neuhoff C, Reinhardt D, de Haas

V, Hasle H, et al. Normal karyotype is a poor prognostic factor in

myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica. 2014;99:299–307.

Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J,

et al. Minimal residual disease-directed therapy for childhood

acute myeloid leukaemia: results of the AML02 multicentre trial.

Lancet Oncol. 2010;11:543–52.

Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, et al.

Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood .2003;102:2960–8.

Kanezaki R, Toki T, Terui K, Xu G, Wang R, Shimada A, et al.

Down syndrome and GATA1 mutations in transient abnormal

myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010;116:4631–8.

10. Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D,

et al. Highly sensitive detection of GATA1 mutations in patients

with myeloid leukemia associated with Down syndrome by

combining Sanger and targeted next generation sequencing. Genes

Chromosomes Cancer. 2020;59:160–7.

11. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC,

Hirsch BA, et al. Residual disease detected by multidimensional

flowcytometry signifies high relapse risk in patients with de novo

acute myeloid leukemia:a report from Children’s Oncology

Group. Blood 2012;120:1581–8.

12. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M,

et al. Prospective study of a pirarubicin, intermediate-dose

cytarabine, and etoposide regimen in children with Down

syndrome and acute myeloid leukemia: the Japanese

Childhood AML Cooperative Study Group. J Clin Oncol.

2007;25:5442–7.

13. Al-Ahmari A, Shah N, Sung L, Zipursky A, Hitzler J. Long-term

results of an ultra low-dose cytarabine-based regimen for the

treatment of acute megakaryoblastic leukaemia in children with

Down syndrome. Br J Haematol. 2006;133:646–8.

14. Nakashima K, Hasegawa D, Tomizawa D, Miyamura T, Hama A,

Iwamoto S, et al. Characteristics and outcomes of children

with acute myeloid leukemia and Down syndrome who are

ineligible for clinical trials due to severe comorbidities.

Pediatr Blood Cancer. 2019;66:e27942 https://doi.org/10.1002/

pbc.27942

Affiliations

Takashi Taga 1 Shiro Tanaka2 Daisuke Hasegawa 3 Kiminori Terui4 Tsutomu Toki 4 Shotaro Iwamoto 5

Hidefumi Hiramatsu 6 Takako Miyamura 7 Yoshiko Hashii8 Hiroshi Moritake 9 Hideki Nakayama 10

Hiroyuki Takahashi 11 Akira Shimada12 Tomohiko Taki13 Etsuro Ito 4 Asahito Hama 14 Masafumi Ito15

Katsuyoshi Koh 16 Daiichiro Hasegawa17 Akiko M. Saito18 Souichi Adachi19 Daisuke Tomizawa 20

Department of Pediatrics, Shiga University of Medical Science,

Otsu, Japan

11

Department of Pediatrics, Toho University, Tokyo, Japan

12

Department of Pediatrics, Okayama University Graduate School of

Medicine, Okayama, Japan

13

Laboratory of Clinical Hematology, Department of Medical

Technology, Kyorin University Faculty of Health Sciences,

Mitaka, Japan

Department of Clinical Biostatistics, Graduate School of Medicine

Kyoto University, Kyoto, Japan

Department of Pediatrics, St Luke’s International Hospital,

Tokyo, Japan

Department of Pediatrics, Hirosaki University Graduate School of

Medicine, Hirosaki, Japan

14

Department of Hematology and Oncology, Children’s Medical

Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

Department of Pediatrics, Mie University Graduate School of

Medicine, Tsu, Japan

15

Department of Pathology, Japanese Red Cross Nagoya First

Hospital, Nagoya, Japan

Department of Pediatrics, Graduate School of Medicine Kyoto

University, Kyoto, Japan

16

Department of Hematology/Oncology, Saitama Children’s

Medical Center, Saitama, Japan

Department of Pediatrics, Osaka University Graduate School of

Medicine, Suita, Japan

17

Department of Hematology/Oncology, Hyogo Children’s Medical

Center, Kobe, Japan

Department of Cancer Immunotherapy, Osaka University

Graduate School of Medicine, Suita, Japan

18

Clinical Research Center, National Hospital Organization Nagoya

Medical Center, Nagoya, Japan

Division of Pediatrics, Department of Reproductive and

Developmental Medicine, Faculty of Medicine, University of

Miyazaki, Miyazaki, Japan

19

Human Health Science, Kyoto University, Kyoto, Japan

20

Division of Leukemia and Lymphoma, Children’s Cancer Center,

National Center for Child Health and Development, Tokyo, Japan

10

Department of Pediatrics, Kyushu Cancer Center, Fukuoka, Japan

...